Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 242 posts found.

takeda_usa_pharmaceuticals_u

Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage

November 7, 2019
Research and Development Takeda, dengue, pharma

Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …

News
takeda_usa_pharmaceuticals_u

Takeda to jettison non-core asset portfolio to Stada for $660 million

November 6, 2019
Research and Development, Sales and Marketing Stada, Takeda, pharma

Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …

News

Redefining the value of medicines with patients at the centre

November 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma

Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …

Feature
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
takeda_world

Takeda’s investigational therapy shows promise as cytomegalovirus treatment

September 25, 2019
Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma

New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …

News
japan-112722_640

Lundbeck and Takeda’s depression drug approved in Japan

September 20, 2019
Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma

Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …

News

NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks

September 18, 2019
Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma

UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …

News

Takeda signs deal with Sosei Heptares worth $1.2 billion

August 6, 2019
Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei

Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit

This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …

News
takeda_deerfield_hq

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

June 26, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing Shire, Takeda, US, pharma

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of …

News
entrance_takeda_i020_v1

Takeda’s Ninlaro fails to meet one of two primary endpoints in Phase 3 trial

June 6, 2019
Research and Development TOURMALINE-AL1, Takeda, pharma, phase 3, trial Ninlaro

Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …

News
novartis_window

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

May 9, 2019
Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …

News

Takeda opens R&D facility in San Diego, California

May 2, 2019
Manufacturing and Production, Research and Development CNS, GI, Japan, Takeda, california, neuroscience, san diego

Japanese-firm Takeda pharmaceuticals has opened a new research facility in San Diego, California. The 165,000ft2 research centre will employ 250 …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023